Guest
Guest
Jan 01, 2026
2:54 AM
|
Despite the promising nature of their research, Synaptigen faces significant challenges, including high R&D costs, long development timelines, and the inherent complexity of neurodegenerative diseases. The heterogeneity of these conditions means that therapies must be tailored to individual patient profiles, requiring sophisticated diagnostic tools and personalized treatment regimens. Additionally, navigating regulatory approval for novel therapies involving gene editing, stem cells, and regenerative approaches involves rigorous safety evaluations and extensive clinical testing. However, Synaptigen’s strategic planning, innovative research, and collaborative approach position them well to overcome these hurdles and make meaningful contributions to the field of neurodegeneration. Synaptigen
|
